Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Status Recruiting

Clinical Trial Summary

This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with nivolumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may kill more tumor cells.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03543969
Study type	Interventional
Source	H. Lee Moffitt Cancer Center and Research Institute
Contact
Status	Recruiting
Phase	Early Phase 1
Start date	June 14, 2018
Completion date	July 2028

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04062032` - Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma	Phase 2
Completed	`NCT03620019` - Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma	Phase 2
Active, not recruiting	`NCT03291002` - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC	Phase 1
Completed	`NCT04534309` - Behavioral Weight Loss Program for Cancer Survivors in Maryland	N/A
Completed	`NCT00962845` - Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery	Early Phase 1
Completed	`NCT00324623` - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma	Phase 1
Completed	`NCT00096382` - Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00104845` - Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	Phase 1
Completed	`NCT00089193` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma	Phase 2
Completed	`NCT00072124` - Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma	Phase 3
Completed	`NCT00072085` - Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma	Phase 2
Active, not recruiting	`NCT00039234` - Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver	Phase 3
Completed	`NCT00049010` - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma	N/A
Completed	`NCT00042783` - Vaccine Therapy in Treating Patients With Stage IV Melanoma	Phase 2
Completed	`NCT00006022` - Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer	Phase 1
Completed	`NCT00020358` - Vaccine Therapy in Treating Patients With Melanoma	Phase 2
Completed	`NCT00006385` - Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00005610` - Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung	Phase 2
Recruiting	`NCT03767348` - Study of RP1 Monotherapy and RP1 in Combination With Nivolumab	Phase 2
Withdrawn	`NCT00006126` - Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery	Phase 1